Tolga Tanguler
CIK: 0001849458
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (97 total)
- Jun 25, 2026LXEO
Lexeo Therapeutics, Inc.
Award(A)DirectStock Option (right to buy)
35K shares- - Mar 4, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct350 shares at avg. $323.01$113K - Mar 4, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct289 shares at avg. $321.82$93K - Mar 4, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct208 shares at avg. $325.67$68K - Mar 4, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct272 shares at avg. $324.88$88K - Mar 4, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct767 shares at avg. $323.84$248K - Mar 4, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct106 shares at avg. $319.03$34K - Mar 4, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct102 shares at avg. $320.01$33K - Mar 4, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct215 shares at avg. $320.81$69K - Mar 2, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct47 shares at avg. $323.62$15K - Mar 2, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Award(A)Direct4.8K shares- - Mar 2, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct392 shares at avg. $326.81$128K - Mar 2, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct329 shares at avg. $327.67$108K - Mar 2, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct100 shares at avg. $328.71$33K - Mar 2, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct258 shares at avg. $325.63$84K - Mar 2, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct37 shares at avg. $332.64$12K - Mar 2, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct90 shares at avg. $324.65$29K - Mar 2, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct81 shares at avg. $330.85$27K - Mar 2, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct170 shares at avg. $329.71$56K - Mar 2, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct94 shares at avg. $331.93$31K - Feb 27, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Exercise(M)Direct1.7K shares- - Feb 13, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct2K shares at avg. $310.08$607K - Feb 12, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Award(A)Direct4K shares- - Jan 12, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct39 shares at avg. $353.95$14K - Jan 12, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct42 shares at avg. $355.16$15K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 25, 2026 |  LXEO Lexeo Therapeutics, Inc. | Award(A) Stock Option (right to buy) | 35,000 | - | - | Direct |
| Mar 4, 2026 |  ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 350 | $323.01 | $113,054 | Direct |
| Mar 4, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 289 | $321.82 | $93,006 | Direct |
| Mar 4, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 208 | $325.67 | $67,739 | Direct |
| Mar 4, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 272 | $324.88 | $88,367 | Direct |
| Mar 4, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 767 | $323.84 | $248,385 | Direct |
| Mar 4, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 106 | $319.03 | $33,817 | Direct |
| Mar 4, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 102 | $320.01 | $32,641 | Direct |
| Mar 4, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 215 | $320.81 | $68,974 | Direct |
| Mar 2, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 47 | $323.62 | $15,210 | Direct |
| Mar 2, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Award(A) | 4,769 | - | $0 | Direct |
| Mar 2, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 392 | $326.81 | $128,110 | Direct |
| Mar 2, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 329 | $327.67 | $107,803 | Direct |
| Mar 2, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 100 | $328.71 | $32,871 | Direct |
| Mar 2, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 258 | $325.63 | $84,013 | Direct |
| Mar 2, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 37 | $332.64 | $12,308 | Direct |
| Mar 2, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 90 | $324.65 | $29,218 | Direct |
| Mar 2, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 81 | $330.85 | $26,799 | Direct |
| Mar 2, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 170 | $329.71 | $56,051 | Direct |
| Mar 2, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 94 | $331.93 | $31,201 | Direct |
| Feb 27, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Exercise(M) | 1,666 | - | $0 | Direct |
| Feb 13, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 1,959 | $310.08 | $607,448 | Direct |
| Feb 12, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Award(A) | 4,000 | - | $0 | Direct |
| Jan 12, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 39 | $353.95 | $13,804 | Direct |
| Jan 12, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 42 | $355.16 | $14,917 | Direct |
1-25 of 97 transactions
About Tanguler Tolga
Tanguler Tolga (SEC CIK 0001849458) files insider reports with the SEC as Director of Lexeo Therapeutics, Inc. (LXEO) and EVP, Chief Commercial Officer of ALNYLAM PHARMACEUTICALS, INC. (ALNY).
Signal8 holds 15 ownership filings by Tanguler Tolga (1 Form 3, 14 Form 4), filed between Nov 13, 2024 and Jun 29, 2026. Those filings report 97 transactions, from Nov 11, 2024 to Jun 25, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Tanguler Tolga's filings is in NEW YORK, NY.
Recent filings by Tanguler Tolga
- Jun 25, 2026: Grant or award of LXEO derivative securities (Form 4, code A).
- Mar 4, 2026: Open-market sales of ALNY shares (8 lines, Form 4, code S).
- Mar 2, 2026: Open-market sale of ALNY shares (Form 4, code S).
- Mar 2, 2026: Grant or award of ALNY shares (Form 4, code A).
- Mar 2, 2026: Open-market sales of ALNY shares (9 lines, Form 4, code S).
Other insiders filing for Lexeo Therapeutics, Inc. (LXEO)
- Tamayo Louis Edward, Chief Financial Officer
- Bhalla Narinder Pal, Chief Medical Officer
- Otero Jose Manuel, Chief Operating Officer
- Townsend Richard Nolan, Chief Executive Officer
- Altschuler Steven, Director
- Agger Mette Kirstine, Director